Neuromuscular Study Group 2026 (NMSG)

Back

Delivering for DMD: Leveraging the FORCE™ platform to deliver exon skipping oligonucleotides for a broad set of DMD patients (poster)

View

HARMONIA Study Design: A Global Phase 3 Trial Assessing the Efficacy and Safety of Zeleciment Basivarsen in DM1 (poster)

View

©2026 Dyne Therapeutics, Inc. All rights reserved MED-00978. Date of preparation: July 2026.